300814-88-4

Basic information

• Product Name: 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)-
• Synonyms: 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)-;2-(2-AMino-4-(thiophen-2-yl)thiazol-5-yl)acetic acid;2-Amino-4-(2-thienyl)-5-thiazoleacetic acid
• CAS NO: 300814-88-4
• Molecular Formula: C9H8N2O2S2
• Molecular Weight: 240
• Mol File: 300814-88-4.mol

Chemical Properties

• Appearance: /
• Density: 1.534
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)-(300814-88-4)
• EPA Substance Registry System: 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)-(300814-88-4)

Safety Data

• Hazardous Substances Data: 300814-88-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)is used as a building block for the synthesis of various drugs. Its unique structure and properties make it a promising candidate for the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Agricultural Industry:
In the agricultural sector, 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)is used as a building block for the synthesis of agrochemicals. Its potential as a precursor for the development of new pesticides and other agrochemicals is being explored, with the aim of enhancing crop protection and yield.
Used in Research and Development:
5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)is also used in research and development for exploring its biological activity and potential pharmacological and pesticidal properties. Ongoing research aims to uncover its full potential and develop new applications for this versatile compound.

Upstream product

• 53515-21-2 3-bromo-4-oxo-4-thiophen-2-yl-butyric acid 
• 17356-08-0 thiourea 
• 4653-08-1 4-oxo-4-thiophen-2-yl-butyric acid 
• 65358-86-3 ethyl 3-bromo-4-oxo-4-(thiophen-2-yl)butanoate 
• 59086-25-8 ethyl 4-oxo-4-(thiophen-2-yl)butanoate 
• 685563-46-6 C₁₁H₁₂N₂O₂S₂ 

Relevant articles and documents

Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing

GPR81, which exhibits a high degree of homology with GPR109a, has been recently identified as a lactate receptor. Similar to GPR109a, the activation of GPR81 by lactate suppresses lipolysis, suggesting that GPR81 may be a potential drug target for treating dyslipidemia. In addition, the fact that GPR81 is expressed only in adipocytes, whereas GPR109a is expressed in various tissues and cells, including Langerhans cells, which are considered responsible for flushing, indicates that targeting GPR81 could lead to the development of antidyslipidemia agents with a reduced risk of this side effect. However, the pharmacological role of GPR81 remains largely unclear, mainly because of the lack of potent and selective surrogate GPR81 agonists suitable for in vivo studies. In the present study, we showed that lactate-induced suppression of lipolysis in explants of white adipose tissue (WAT) depends on the presence of GPR81. We also performed high-throughput screening (HTS) and identified four novel chemical clusters as GPR81 agonists. Chemical optimization of aminothiazole derivatives led to the discovery of a lead compound with improved potency. The compound inhibited lipolysis in differentiated 3T3-L1 adipocytes. Finally, intraperitoneal administration of this compound suppressed lipolysis in mice at doses that did not cause cutaneous flushing. This is the first description of a 50 nM GPR81 selective agonist with in vivo efficacy, without the side effect, i.e., flushing. These results suggest that GPR81 is an attractive drug target for treating dyslipidemia without the risk of flushing.